肿瘤细胞治疗研究
英文原题：Novel therapeutic strategies leveraging T(H)9 cell anticancer functions.
TH9细胞是CD4+辅助性T细胞的一个独特亚群，以产生IL-9为特征，已成为肿瘤免疫学中的关键参与者。
TH9 细胞是 CD4+ T 辅助细胞的一个独特亚群，以产生 IL-9 为特征，已成为癌症免疫学中的关键参与者。最初因其在过继细胞转移治疗黑色素瘤时具有强效抗肿瘤活性而受到认识，近期研究揭示了其更为复杂且依赖环境的作用，其中 TH9 细胞通过多种机制支持抗肿瘤免疫。本综述探讨了 TH9 细胞在癌症中的贡献，强调其在响应肿瘤微环境线索如缺氧、代谢变化以及与基质细胞和髓系细胞相互作用中的重要性。我们还重点介绍了利用 TH9 细胞抗癌功能的新型治疗策略，包括过继转移、细胞因子工程和代谢重编程，以及它们整合到现有免疫治疗策略中的潜力，包括免疫检查点抑制剂和 CAR-T 细胞疗法。理解驱动 TH9 细胞介导免疫的机制将有助于确认其在下一代免疫治疗策略中的相关性。
T H 9 cells, a distinct subset of CD4 + T helper cells characterized by IL-9 production, have emerged as key players in cancer immunology. Initially recognized for their potent antitumor activity upon adoptive cell transfer against melanoma, recent studies have revealed a more complex and context-dependent role, where T H 9 cells support antitumor immunity through multiple mechanisms. This review explores the contribution of T H 9 cells in cancer, emphasizing their importance in response to tumor microenvironmental cues such as hypoxia, metabolic changes, and interactions with stromal and myeloid cells. We also highlight novel therapeutic strategies leveraging T H 9 cell anticancer functions, including adoptive transfer, cytokine engineering, and metabolic reprogramming, as well as their potential integration into existing immunotherapy strategies, including immune checkpoint inhibitors and CAR-T cell therapies. Understanding the mechanisms responsible for driving T H 9 cell-mediated immunity will be instrumental to confirm their relevance in next-generation immunotherapeutic strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
